References (Supplied by CrossRef)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study (UKPDS) Group et al.
Patient adherence to medication requirements for therapy of type 2 diabetes
Bailey et al.
Int J Clin Pract 2011
10-year follow-up of intensive glucose control in type 2 diabetes
Holman et al.
N Engl J Med 2008
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
Ohkubo et al.
Diabetes Res Clin Pract 1995
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton et al.
Insulin therapy for type 2 diabetes
Swinnen et al.
Diabetes Care 2009
GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence
Meloni et al.
Diabetes Obes Metab 2013
The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis
Potts et al.
PLoS One 2015
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
Flint et al.
J Clin Invest 1998
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
Buse et al.
Ann Intern Med 2011
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Seino et al.
Diabetes Obes Metab 2012